NASDAQ:SMTI Sanara MedTech (SMTI) Stock Forecast, Price & News $31.59 -1.52 (-4.59%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$31.55▼$33.3050-Day Range$33.11▼$45.9952-Week Range$26.75▼$50.18Volume16,823 shsAverage Volume16,787 shsMarket Capitalization$269.15 millionP/E RatioN/ADividend YieldN/APrice Target$59.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Sanara MedTech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.8% Upside$59.00 Price TargetShort InterestBearish3.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.31) to $2.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector719th out of 969 stocksSurgical Appliances & Supplies Industry14th out of 21 stocks 3.5 Analyst's Opinion Consensus RatingSanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.00, Sanara MedTech has a forecasted upside of 86.8% from its current price of $31.59.Amount of Analyst CoverageSanara MedTech has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.82% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Sanara MedTech has recently decreased by 0.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSanara MedTech does not currently pay a dividend.Dividend GrowthSanara MedTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMTI. Previous Next 1.8 News and Social Media Coverage News SentimentSanara MedTech has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sanara MedTech this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sanara MedTech insiders have not sold or bought any company stock.Percentage Held by Insiders55.20% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.83% of the stock of Sanara MedTech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sanara MedTech are expected to grow in the coming year, from ($0.31) to $2.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanara MedTech is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanara MedTech is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSanara MedTech has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sanara MedTech (NASDAQ:SMTI) StockSanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Read More SMTI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMTI Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comSanara MedTech's (SMTI) "Overweight" Rating Reaffirmed at Cantor FitzgeraldSeptember 27, 2023 | americanbankingnews.comFinancial Comparison: Sanara MedTech (NASDAQ:SMTI) vs. OceanTech Acquisitions I (NASDAQ:OTEC)September 28, 2023 | Behind the Markets (Ad)New Breakthrough "Living Software" Has Been…New Breakthrough "Living Software" Has Been... Ukraine's "Secret Weapon" Against Russia The Washington Post Reports: "It's a big reason David is beating Goliath..." The Wall Street Journal Reports: "it's a technical revolution." Jeff Bezos Said: "It's in the realm of science fiction." Early investors can reap 5,633% gains on the small company revolutionizing warfare >>>September 21, 2023 | americanbankingnews.comSanara MedTech (NASDAQ:SMTI) & Pathfinder Cell Therapy (OTCMKTS:PFND) Critical ComparisonSeptember 13, 2023 | msn.comSanara MedTech: Surgical Sales Set To Accelerate While Post Acute Care Platform DevelopsSeptember 12, 2023 | finance.yahoo.comSanara MedTech to Participate in Two Upcoming ConferencesAugust 31, 2023 | finance.yahoo.comWe're Not Very Worried About Sanara MedTech's (NASDAQ:SMTI) Cash Burn RateAugust 18, 2023 | msn.comCantor Fitzgerald Reiterates Sanara MedTech (SMTI) Overweight RecommendationSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 14, 2023 | finance.yahoo.comSanara MedTech Inc. Announces Second Quarter 2023 ResultsAugust 2, 2023 | finance.yahoo.comSanara MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products BusinessAugust 1, 2023 | finance.yahoo.comSanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call DatesJuly 24, 2023 | finance.yahoo.comSanara MedTech Inc.'s (NASDAQ:SMTI) Path To ProfitabilityJuly 15, 2023 | finance.yahoo.comSMTI - Sanara MedTech Inc.June 27, 2023 | finance.yahoo.comSanara MedTech Inc.'s (NASDAQ:SMTI) largest shareholders are individual investors with 32% ownership, insiders own 32%June 14, 2023 | msn.comSanara MedTech: Qualified Growth Company, Market Selloff UnjustifiedMay 24, 2023 | msn.comDown -14.23% in 4 Weeks, Here's Why Sanara MedTech Inc. (SMTI) Looks Ripe for a TurnaroundMay 15, 2023 | msn.comSanara MedTech: Q1 Earnings InsightsMay 15, 2023 | finance.yahoo.comSanara MedTech Inc. Announces First Quarter 2023 ResultsMay 5, 2023 | finance.yahoo.comSanara MedTech Inc.'s (NASDAQ:SMTI) Price In Tune With RevenuesMay 3, 2023 | finance.yahoo.comSanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call DatesApril 4, 2023 | finance.yahoo.comSanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical SolutionMarch 24, 2023 | insidermonkey.comSanara MedTech Inc. (NASDAQ:SMTI) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finance.yahoo.comWe Think Sanara MedTech (NASDAQ:SMTI) Can Afford To Drive Business GrowthMarch 20, 2023 | finance.yahoo.comSanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 ResultsMarch 17, 2023 | benzinga.comEarnings Outlook For Sanara MedTechMarch 6, 2023 | finance.yahoo.comSanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Earnings Release and Conference Call DatesSee More Headlines Receive SMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter. Email Address SMTI Company Calendar Last Earnings8/14/2023Today9/28/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMTI CUSIPN/A CIK714256 Webwww.wndm.com Phone(817) 529-2300FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Forecast$59.00 High Stock Price Forecast$59.00 Low Stock Price Forecast$59.00 Forecasted Upside/Downside+86.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,940,000.00 Net Margins-14.39% Pretax Margin-17.57% Return on Equity-21.41% Return on Assets-15.01% Debt Debt-to-Equity RatioN/A Current Ratio1.84 Quick Ratio1.39 Sales & Book Value Annual Sales$45.84 million Price / Sales5.87 Cash FlowN/A Price / Cash FlowN/A Book Value$5.02 per share Price / Book6.29Miscellaneous Outstanding Shares8,520,000Free Float3,818,000Market Cap$269.15 million OptionableNot Optionable Beta1.82 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Ronald T. Nixon (Age 67)Exec. Chairman Mr. Zachary B. Fleming (Age 48)Chief Exec. Officer Comp: $593.64kMr. Michael D. McNeil (Age 58)CFO & Corp. Sec. Comp: $438.68kDr. Christopher A. Morrison FACHM (Age 53)FAPWCA, FCCWS, M.D., Pres of Telehealth Services Comp: $156kMr. Callon NicholsVP of Corp. OperationsMr. Bill FitzgeraldChief Compliance OfficerMs. Tricia MattesonVP of MarketingDr. Rebecca Erin Mcmahon (Age 38)Pres of R&D Mr. Ryan PhillipsPres of BiologicsMr. Seth YonPres of CommercialMore ExecutivesKey CompetitorsAnzu Special Acquisition Corp INASDAQ:ANZUJin Medical InternationalNASDAQ:ZJYLInogenNASDAQ:INGNVicarious SurgicalNYSE:RBOTAvanos MedicalNYSE:AVNSView All CompetitorsInsiders & InstitutionsBarclays PLCBought 757 shares on 9/21/2023Ownership: 0.009%California State Teachers Retirement SystemBought 1,263 shares on 8/21/2023Ownership: 0.015%Citadel Advisors LLCSold 235 shares on 8/15/2023Ownership: 0.214%Quadrature Capital LtdBought 6,644 shares on 8/15/2023Ownership: 0.207%Wells Fargo & Company MNBought 1,559 shares on 8/15/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions SMTI Stock - Frequently Asked Questions Should I buy or sell Sanara MedTech stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares. View SMTI analyst ratings or view top-rated stocks. What is Sanara MedTech's stock price forecast for 2023? 1 brokerages have issued 1 year target prices for Sanara MedTech's shares. Their SMTI share price forecasts range from $59.00 to $59.00. On average, they expect the company's stock price to reach $59.00 in the next year. This suggests a possible upside of 86.8% from the stock's current price. View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts. How have SMTI shares performed in 2023? Sanara MedTech's stock was trading at $45.50 at the start of the year. Since then, SMTI shares have decreased by 30.6% and is now trading at $31.59. View the best growth stocks for 2023 here. When is Sanara MedTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our SMTI earnings forecast. How were Sanara MedTech's earnings last quarter? Sanara MedTech Inc. (NASDAQ:SMTI) announced its earnings results on Monday, August, 14th. The company reported ($0.22) EPS for the quarter. The business earned $15.75 million during the quarter. Sanara MedTech had a negative trailing twelve-month return on equity of 21.41% and a negative net margin of 14.39%. What other stocks do shareholders of Sanara MedTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), Aurora Cannabis (ACB), AC Immune (ACIU) and Applied Genetic Technologies (AGTC). What is Sanara MedTech's stock symbol? Sanara MedTech trades on the NASDAQ under the ticker symbol "SMTI." Who are Sanara MedTech's major shareholders? Sanara MedTech's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.06%), Geode Capital Management LLC (0.82%), State Street Corp (0.62%), Northern Trust Corp (0.37%), Citadel Advisors LLC (0.21%) and Quadrature Capital Ltd (0.21%). Insiders that own company stock include Shawn M Bowman and Zachary B Fleming. View institutional ownership trends. How do I buy shares of Sanara MedTech? Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sanara MedTech's stock price today? One share of SMTI stock can currently be purchased for approximately $31.59. How much money does Sanara MedTech make? Sanara MedTech (NASDAQ:SMTI) has a market capitalization of $269.15 million and generates $45.84 million in revenue each year. The company earns $-7,940,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. How many employees does Sanara MedTech have? The company employs 101 workers across the globe. How can I contact Sanara MedTech? Sanara MedTech's mailing address is 1200 Summit Avenue Suite 414, Fort Worth TX, 76102. The official website for the company is www.wndm.com. The company can be reached via phone at (817) 529-2300 or via email at ir@sanaramedtech.com. This page (NASDAQ:SMTI) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.